AIM at Melanoma Opens First Melanoma Tissue Bank in the U.S.

AIM at Melanoma Opens First Melanoma Tissue Bank in the U.S.

Publication date: Apr 06, 2019

SAN RAFAEL, Calif. , April 5, 2019 /PRNewswire/ — AIM at Melanoma announces the grand opening of the first branch of the International Melanoma Tissue Bank Consortium (IMTBC) at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center.

The IMTBC is a global first because of the following combination of factors: “The primary tumor is the holy grail of resources for melanoma researchers,” says John M. Kirkwood, MD, Usher Professor of Medicine, Dermatology and Translational Science and co-Leader, Melanoma and Skin Cancer Program, UPMC Hillman Cancer Center.

“Fifteen years ago, many researchers told me that a collaborative fresh-frozen primary tissue bank would propel research, but they also told me it would be impossible to accomplish,” says Val Guild, the Founder & President of AIM at Melanoma, who lost her 26 year old daughter, Charlie, to the disease in 2003.

Concepts Keywords
AIM Immunotherapies
Australia Melanoma
Critical Mass Medicine
Dermatology RTT
Holy Grail Clinical medicine
Immunotherapies Health
Melanoma Cancer
Melanomas Immunotherapy
Pittsburgh SAN
President Melanomas
Primary Tumor Tumors
SAN RAFAEL
UPMC
Usher

Semantics

Type Source Name
disease MESH Skin Cancer
gene UNIPROT RNF128
gene UNIPROT FBN1
disease DOID Cancer
disease MESH Cancer
gene UNIPROT TNFSF13
gene UNIPROT ANP32B
gene UNIPROT CD5L
gene UNIPROT CD69
gene UNIPROT DNMT1
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
gene UNIPROT BANK1
gene UNIPROT NAA50
gene UNIPROT CNOT8
drug DRUGBANK Nonoxynol-9
drug DRUGBANK L-Valine
gene UNIPROT FBXW7
disease DOID Skin Cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *